

**Role of High Sensitivity C-Reactive protein
In The Prediction of Future Cardiovascular Events in
Patients Presenting With Acute Coronary Syndromes**

**Thesis submitted for partial fulfillment of Masters degree in
Cardiology**

Presented By

Ahmed Mohamed El-Damaty, M.B.B.Ch

Under the supervision of

Sherif El-Tobgi, MD

Professor of Cardiology

Cairo University

Amani El-Kholy, MD

Professor of Clinical Pathology

Cairo University

Sameh Ahmed Salama, MD

Associate professor of Cardiology

Cairo University

Cairo University

2008

Abstract

Background and aims:

Inflammation appears to be pivotal in all phases of atherosclerosis from the fatty streak lesion to acute coronary syndromes. An important marker of inflammation is C-reactive protein. We thought to test the hypothesis that CRP measured at admission with acute coronary syndrome and at regular follow up durations is predictive of future cardiovascular events and to assess the relation of CRP levels to the complexity of coronary stenoses and to the coronary score as a surrogate of the total atherosclerotic burden.

Methods:

We prospectively recruited 91 patients presenting with acute coronary syndromes including those with ST elevation, clinical examination excludes those with evidence of infection or inflammation. All patients underwent coronary angiography (lesions were classified according to complexity into type A, B and C and coronary score was calculated by summing percent stenosis score times extent score over 15 coronary segments). Serum samples for measuring CRP level was withdrawn then patients were followed at 1, 4, 8 and 12 months and assessed for the occurrence of composite end points of nonfatal MI, UA or cardiac death. Samples for CRP were withdrawn in the 1st three follow up visits.

Results:

Admission CRP level could not predict future cardiovascular events ($P=0.9$) and did not correlate with complexity of coronary stenoses ($P=0.42$), meanwhile CRP at all follow up visits (1m, 4m and 8m) correlated with both events ($P=0.001, 0.004$ and 0.01 respectively) and lesion complexity ($P=0.001, 0.01$ and <0.001 respectively), CRP that preceded the event "pre-event CRP" was significantly higher than samples not followed by events. A cutoff value of 7.3 mg/l or 4.3 fold rise in CRP level had the highest sensitivity and specificity in detecting events. Despite being higher in patients developing events, coronary score did not correlate with any of the CRP samples.

Conclusions:

CRP done at admission is likely to be confounded by the inflammatory outburst that occurs secondary to the occurrence of myocardial necrosis but it could be useful in following patients after acute coronary syndromes; its rise prior to the event may also indicate that CRP may not be a mere marker of plaque instability but also act as a mediator through its pro-inflammatory and pro-atherogenic effects. CRP is not a mere marker of the angiographic atherosclerotic burden but instead, a marker of coronary artery disease activity.

Key Words :

C-Reactive protein - Acute Coronary Syndromes - Cardiovascular Events

CONTENTS

Contents	2
Acknowledgments	3
List of tables	4
List of figures	6
Introduction	8
Aim of the work	9
Review of literature	10
• Inflammation and atherosclerosis.	10
• Inflammation and acute coronary syndromes.	16
• Inflammatory markers.	20
• Hs-CRP and the cardiovascular risk.	30
• Other inflammatory markers and the cardiovascular risk.	47
• AHA/CDC recommendations for the use of inflammatory markers for assessment of the cardiovascular risk.	52
Material and methods	56
Results	61
Discussion	75
Conclusions	82
Summary	83
References	88
Master table (appendix)	
Arabic summary	

Acknowledgements

- I would like to thank professor *Sherif El-Tobgi* for his supervision and invaluable advice in planning this work; he also kept providing me with the most valuable scientific papers addressing this work. Moreover, I would like to thank him as the president of the conference of the Diamond jubilee of the cardiology department that funded the laboratory kits used in this study.
- My sincerest thanks to Dr. *Sameh Salama* who supervised the planning and execution of this study from beginning to end and personally performed the great majority of the echocardiographic procedures, I thank him for his patience, support and constructive criticism without which the completion of this work would not have been possible.
- I would like to thank Dr. *Amani el-Kholy* and Dr. *Mervat Gaber* at the laboratory for their help in managing the laboratory aspect of this work.
- I would like to express my thanks to my *father* and my *wife* who continued supporting me in all the stages of this work.
- Last but not least, to the soul of my *mother* who has always been an inspiration and to my young child *Karim* who has always been a push to a better future.

List of tables (page)

- Table 1:** Inflammatory Markers for Potential Clinical Use. (19)
- Table 2:** Biological properties and function of the CRP. (22)
- Table 3:** Possible mechanisms of action of leucocytes in Coronary Heart Disease. (29)
- Table 4:** Prognostic value of elevated cardiac troponin and CRP within 24 hrs in the total unstable angina population. (41)
- Table 5:** Correlation between serum CRP and the angiographic data of 700 patients with CSA. (45)
- Table 6:** Multivariate predictors of the combined end point of cardiac death, non fatal MI, class III unstable angina in the 700 patients with CSA. (45)
- Table 7:** Studies correlating leukocyte count and coronary heart disease in subjects with acute myocardial infarction or unstable angina. (51)
- Table 8:** Recommendations for the use of inflammatory markers in clinical and public health services. (53)
- Table 9:** Type of the lesion; lesions were classified according to guidelines of percutaneous coronary angioplasty into type A, type B and type C. (58)
- Table 10:** Baseline characteristics of 91 patients presenting with acute coronary syndromes. (61)
- Table 11:** Study population classified according to the type of therapy. (61)
- Table 12:** Study population classified according to the study endpoints. (62)
- Table 13:** The relation between different risk factors and the occurrence of events in the study population. (63)
- Table 14:** Routine laboratory data in eventful vs. uneventful cases. (64)
- Table 15:** CRP 0, done at admission, in the eventful vs. uneventful group. (65)
- Table 16:** Mean CRP 1, CRP2 and CRP3; at 1month, 4months and 8months of follow up; in the eventful vs. the uneventful group. (65)
- Table 17:** Pre-event CRP compared with CRP levels in the uneventful group at different follow up durations. (66)
- Table 18:** Pre-event CRP in the eventful group vs. CRP at follow up not followed by events. (67)
- Table 19:** Delta pre-event CRP vs. delta uneventful CRP. (68)
- Table 20:** Pre-event CRP among patients with different study endpoints. (70)
- Table 21:** Correlation between (CRP 0, 1, 2 and 3) and the coronary score. (71)
- Table 22:** CRP 0, 1, 2 and 3 compared among different categories of coronary stenoses. (71)

Table 23: CRP level in STEMI vs. NSTEMI. **(72)**

Table 24: Ejection fraction in the eventful vs. the uneventful group. **(73)**

Table 25: Eventful Vs. uneventful cases among various categories of coronary stenoses. **(73)**

Table 26: Coronary score in the eventful vs. the uneventful group. **(74)**

Table 27: Multivariate predictors of the composite endpoint of death, STEMI, and UA/NSTEMI in the 91 patient included in the study. **(74)**

Table 28: Overview of the studies supporting the prognostic role of CRP at admission in acute coronary syndrome. **(75)**

Table 29: Overview of the studies negating the prognostic role of CRP at admission in acute coronary syndrome. **(76)**

List of figures (page)

- Figure 1:** Activating Effect of LDL Infiltration on Inflammation in the Artery. (10)
- Figure 2:** Inflammatory Role of Macrophage in atherosclerosis. (12)
- Figure 3:** Formation of the fibrofatty plaque. (13)
- FIGURE 4:** Maturation of the Atherosclerotic plaque. (15)
- FIGURE 5:** The thrombotic complications of atherosclerosis. (17)
- FIGURE 6:** A schematic relating extracellular matrix metabolism to intimal inflammation during atherogenesis. (18)
- Figure 7:** Schematic representation of the CRP molecule. (20)
- Figure 8:** Diagrammatic representation of the CRP molecule. (21)
- Figure 9:** The inflammatory cascade. (22)
- Figure10:** Electron micrographs of SAA. (25)
- Figure 11:** Diagrammatic representation of the fibrinogen molecule. (26)
- Figure 12:** Hazard rate ratios for CRP quintiles, relative to the first quintile, in various adjustments. (31)
- Figure 13:** Relative Risk (and 95 Percent Confidence Intervals) of a First Myocardial Infarction associated with Each Increasing Quartile of Base-Line C-Reactive Protein Values, According to the Year of Study Follow-up. (32)
- Figure 14:** Relative Risk of Cardiovascular Events among Apparently Healthy Postmenopausal Women According to Base-Line Levels of Total Cholesterol and Markers of Inflammation. (33)
- Figure 15:** Kaplan-Meier estimates of 10-year total and cardiovascular mortality in 75- to 85-year-old individuals (n=455) according to the baseline CRP level. (34)
- Figure 16:** Receiver operating characteristic analysis to determine the cut-point of peak C-reactive protein level as a predictor of cardiac rupture and 1-year cardiac death. The cut-point of 20 mg/dL showed high sensitivity and specificity to predict both complications. (36)
- Figure 17:** Probability of cardiac events in groups based on different tertiles of C-reactive protein level. (37)
- Figure 18:** Risk stratification by CRP (mg/dl) and rapid assay status expressed as 14- day mortality rate by CRP and rapid cTnT result. (38)
- Figure 19:** Mortality rate at 14 days by CRP and rapid cTnT assay status. (38)
- Figure 20:** Incidence of readmission for instability or myocardial infarction during follow-up according to tertiles of CRP. (39)

- Figure 21:** Kaplan-Meier plot: cumulative freedom from risk of death, myocardial infarction, or refractory angina (D/AMI/RA) within 90 days in patients with CRP levels above or below 1.5 mg/dL. **(39)**
- Figure 22:** Event rates (mortality and MI) according to the patients' CRP status during first 72 h (top panel) and after six months of follow-up (bottom panel). **(40)**
- Figure 23:** Cumulative incidence of all-cause mortality or myocardial infarction (MI) during follow-up by coronary artery disease (CAD) score and C-reactive protein (CRP). **(43)**
- Figure 24:** There was no correlation between CRP level and coronary atherosclerosis score (Pearson correlation coefficient 0.17; R² 5 0.03). **(44)**
- Figure 25:** Baseline characteristics of 91 patients presenting with acute coronary syndromes. **(62)**
- Figure 26:** Study population classified according to the study endpoints. **(62)**
- Figure 27:** The relation between different risk factors and the occurrence of events in the study population. **(64)**
- Figure 28:** CRP0, CRP 1, CRP2 and CRP3; at admission, 1month, 4months and 8months of follow up; in the eventful vs. the uneventful group. **(66)**
- Figure29:** ROC plot for pre-event CRP in predicting events [Data derived from comparing pre-event CRP vs. NPECRP 1(red line), NPECRP2 (blue line) and NPECRP3 (red line) in the eventful group], NPECRP (non pre-event CRP). **(67)**
- Figure30:** ROC plot for delta pre-event CRP in predicting events [Data derived from comparing pre-event CRP vs. NPEDCRP 1(red line), NPEDCRP2 (blue line) and NPEDCRP3 (red line) in the eventful group], NPEDCRP (non pre-event delta CRP). **(69)**
- Figure 31:** Pre-event CRP among patients with different study endpoints. **(70)**
- Figure 32:** Correlation between (CRP 0, 1, 2 and 3) and the coronary score. **(71)**
- Figure 33:** CRP 0, 1, 2 and 3 compared among different categories of coronary stenoses. **(72)**
- Figure 34:** CRP 0 level in STEMI vs. NSTEMI. **(72)**
- Figure 35:** Eventful Vs. uneventful cases among various categories of coronary stenoses. **(73)**

Introduction

Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Recent advances in basic sciences have established a fundamental role of inflammation in mediating all stages of atherosclerosis, i.e. initiation, growth & complications, all represent an inflammatory response to injury as it involves cytokines and other bioactive molecules and cells that are characteristic of inflammation e.g.(macrophages and T-lymphocytes).⁽¹⁾

Acute coronary syndromes are responsible for almost all the morbidity and mortality of coronary artery disease, development of acute coronary syndromes occur with rupture of the fibrous cap overlying vulnerable atherosclerotic plaques with subsequent thrombosis leading to total or subtotal occlusion of a main epicardial coronary artery. The strength of the fibrous cap represents a balance between the extracellular matrix synthesis by smooth muscle cells -SMC's- and its degradation by proteolytic enzymes. The lipid core of atheromatous plaques contains 2 main types of inflammatory cells: T-lymphocytes which release interferon- γ (IF- γ) that inhibit SMC collagen production & macrophages which release collagen degrading matrix metalloproteinases and elastases, these enzymes promote matrix catabolism.⁽¹⁾

Thus, in states of heightened intimal inflammation, the extracellular matrix that confers biomechanical strength of the plaque's fibrous cap is under double attack; decreased synthesis and increased degradation which results in weakening and thinning of the fibrous cap. Accordingly, inflammatory markers could be taken as a mean to assess the ongoing inflammatory process of atherosclerosis.⁽¹⁾

CRP has been considered the analyte of choice after consideration of the various analytes stabilities, assay precision, accuracy, availability and the presence of standards for proper assay calibration.

Aim of the work

Aim of the work

The aim of this study is to:

1. Test the hypothesis that serial Hs-CRP measurements can predict recurrent future cardiovascular events (i.e. recurrent unstable angina, myocardial infarction or death) in patients presenting with acute coronary syndromes.
2. Assess the relation between Hs-CRP levels and the presence of complex angiographic coronary stenoses, which are known to represent high risk coronary plaques and also correlate the Hs-CRP to the total atherosclerotic burden.
3. Assess the role of different risk factor profiles in predicting the occurrence of future cardiovascular events in patients presenting with acute coronary syndromes.

Review of literature

Review of Literature

Inflammation and atherosclerosis

On initiation of an atherogenic diet rich in cholesterol and saturated fat, one of the first ultrastructural alterations is the accumulation of small lipoprotein particles in the arterial intima⁽²⁾. Lipoprotein particles bind to proteoglycan in the arterial intima and appear to exhibit increased susceptibility to oxidative and other chemical modifications including glycation and enzymatic processing by sphingomyelinase^(3, 4). LDL modification results in local cytokine elaboration, the cytokines then induce increased expression of adhesion molecules for leukocytes that cause their attachment and chemoattractant molecules that direct their migration into the intima. These chemoattractant molecules include 2 groups, monocyte chemoattractant protein 1(MCP1) and a group of T cell chemoattractant chemokines.




FIGURE 1: Activating effect of LDL infiltration on inflammation in the artery

"Inflammation, Atherosclerosis, and Coronary Artery Disease, NEJM, 352; 16 april 21, 2005."

The second morphologically definable event in the initiation of atheroma is leukocyte recruitment and accumulation. Very early after initiation of hypercholesterolemia, leukocytes and T lymphocytes adhere to the endothelium and diapedese between endothelial cell junctions to enter the intima.

The expression of certain leukocyte adhesion molecules on the surface of the endothelial cell regulates the adherence of monocytes and T cells to the endothelium ⁽⁵⁾. Two broad categories of leukocyte adhesion molecules exist, members of the immunoglobulin superfamily that include structures such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), both are expressed on the endothelial cell surface and bind both monocytes and lymphocytes. Adhesion molecules belonging to the immunoglobulin superfamily tend to promote tighter adhesive interactions and immobilization of leukocytes ⁽⁶⁾. Selectins constitute the other broad category of leukocyte adhesion molecules. The prototypical selectin, E-selectin (E for “endothelial,” the cell type that selectively expresses this particular family member), probably has little to do with early atherogenesis. E-selectin preferentially recruits polymorphonuclear leukocytes, a cell type seldom found in early atheroma. Other members of this family, including P-selectin (P for “platelet,” the original source of this adhesion molecule), may play a greater role in leukocyte recruitment in atheroma. Selectins tend to promote saltatory or rolling locomotion of leukocytes over the endothelium ^(7,8).

The monocyte, once recruited to the arterial intima, can there imbibe lipid and become a foam cell, or “lipid-laden macrophage”, instead of the classical LDL receptor, various molecules known as “scavenger” receptors appear to mediate the excessive lipid uptake characteristic of foam cell formation. The longest studied of these receptors belong to the scavenger receptor-A family ^(9,10). These surface molecules bind modified rather than native lipoproteins and apparently participate in their internalization.

Other receptors that bind modified lipoprotein and may participate in foam cell formation include CD36 and macrosialin. Once macrophages have taken up residence in the intima and become foam cells, they frequently replicate. The factors that trigger macrophage cell division in the atherosclerotic plaque likely include macrophage colony-stimulating factor (M-CSF), interleukin-3 and granulocyte-macrophage colony-stimulating factor. ^(9, 10)

Thus far, the scenario of the evolving atheroma has invoked only such lipid-engorged leukocytes constituting what is known as the fatty streak. Withdrawal of the atherogenic diet or treatment with drugs that lower lipoprotein levels in plasma can reduce the extent of established lesions. Thus, fatty streaks composed primarily of macrophages are likely reversible, at least to some extent.




FIGURE 2: Inflammatory role of macrophage in atherosclerosis.

"Inflammation, Atherosclerosis, and Coronary Artery Disease, *NEJM*, 352; 16 april 21, 2005."

The subsequent evolution of atheroma into more complex plaques involves smooth muscle cells as well. The chemoattractants for smooth muscle cells likely include molecules such as platelet-derived growth factor (PDGF), a potent smooth muscle cell chemoattractant secreted by activated macrophages⁽¹⁾. Smooth muscle cells can then divide and elaborate extracellular matrix, promoting extracellular matrix accumulation in the growing atherosclerotic plaque. In this manner, the fatty streak can evolve into a fibrofatty lesion.